dc.contributor.author |
Sen, S |
|
dc.contributor.author |
Tuncer, A |
|
dc.contributor.author |
Ozakbas, S |
|
dc.contributor.author |
Uzunkopru, C |
|
dc.contributor.author |
Baba, C |
|
dc.contributor.author |
Demir, S |
|
dc.contributor.author |
Beckmann, Y |
|
dc.contributor.author |
Gumus, H |
|
dc.contributor.author |
Arslan, G |
|
dc.contributor.author |
Kilic, AK |
|
dc.contributor.author |
Altintas, A |
|
dc.contributor.author |
Yuceyar, N |
|
dc.contributor.author |
Turan, OF |
|
dc.contributor.author |
Tutuncu, M |
|
dc.contributor.author |
Terzi, M |
|
dc.contributor.author |
Acar, P |
|
dc.contributor.author |
Bunul, SD |
|
dc.contributor.author |
Balci, BP |
|
dc.contributor.author |
Bir, LS |
|
dc.contributor.author |
Koseoglu, M |
|
dc.contributor.author |
Mungan, S |
|
dc.contributor.author |
Gunduz, T |
|
dc.contributor.author |
Dogan, IG |
|
dc.contributor.author |
Kotan, D |
|
dc.contributor.author |
Uygunoglu, U |
|
dc.contributor.author |
Ekmekci, O |
|
dc.contributor.author |
Demirkiran, M |
|
dc.contributor.author |
Kamisli, O |
|
dc.contributor.author |
Kabay, SC |
|
dc.contributor.author |
Tamam, Y |
|
dc.contributor.author |
Omerhoca, S |
|
dc.contributor.author |
Sevim, S |
|
dc.contributor.author |
Guler, S |
|
dc.contributor.author |
Kurtuncu, M |
|
dc.contributor.author |
Efendi, H |
|
dc.contributor.author |
Karabudak, R |
|
dc.contributor.author |
Siva, A |
|
dc.date.accessioned |
2023-01-02T08:53:09Z |
|
dc.date.available |
2023-01-02T08:53:09Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
http://hdl.handle.net/11616/86965 |
|
dc.description.abstract |
Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. |
|
dc.description.abstract |
Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. |
|
dc.description.abstract |
Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. |
|
dc.description.abstract |
Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection. |
|
dc.source |
MULTIPLE SCLEROSIS AND RELATED DISORDERS |
|
dc.title |
The Turkish experience of COVID-19 infection in people with NMOSD and |
|